DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) recovered 29.14% of its value since hitting low of $1.51. The recent move of -4.88% drop pushed the stock to close at $1.95 when trading ended on 6/6/2019. At a recent session, the prices were hovering between $1.8 and $2.03. This company shares are 515.38% off its target price of $12 and the current market capitalization stands at $6.3M. The recent change has given its price a -41.55% deficit over SMA 50 and -79.12% deficit over its 52-week high. The stock witnessed -48.47% declines, -32.76% declines and -60.75% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found DMPI’s volatility during a week at 64.07% and during a month it has been found around 31.81%.

DelMar Pharmaceuticals, Inc. 13F Filings

At the end of March reporting period, 4 institutional holders increased their position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) by some 16,589 shares, 6 decreased positions by 127,170 and 5 held positions by -53,710. That puts total institutional holdings at 90,049 shares, according to SEC filings. The stock grabbed 1 new institutional investments totaling 500 shares while 2 institutional investors sold out their entire positions totaling 31,190 shares.

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Insider Trades

Multiple company employees have indulged in significant insider trading. DelMar Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Bell John K has acquired 20,000 shares of DelMar Pharmaceuticals, Inc. (DMPI) in the trading session dated Nov. 16, 2017. These shares are worth $16,200 and were traded at $0.81 each. The SEC filing shows that Zarrabian Saiid performed a purchase of 60,900 shares. The Interim CEO added these shares by way of transaction on Nov. 14, 2017. The company’s shares were assimilated at $0.82 per share worth to an investment of some $49,938 to the account of Zarrabian Saiid.

CEO, BACHA JEFFREY, purchased 10,000 common shares of DelMar Pharmaceuticals, Inc. (DMPI) in the open market. In a transaction dated Oct. 06, 2017, the shares were bought at an average price of $0.87, giving away a sum of $8,700. After this purchase, 63,697 common shares of DMPI are directly owned by the insider, with total stake valued at $124,209.

In the transaction dated Oct. 05, 2017, a great number of shares acquired came courtesy the Chief Financial Officer; Praill Scott added a total of 17,500 shares at an average price of $0.85, amounting to approximately $14,875. The insider now directly owns 47,366 shares worth $92,364.